BUZZ-Embecta rises after agreeing to buy UK device maker Owen Mumford

Reuters03-19

** Shares of medical device maker Embecta EMBC.O rise 2% to $8.99 premarket

** Co says it will buy privately held Owen Mumford in a deal worth up to 150 million pounds ($199.10 million), expanding into drug‑delivery devices beyond diabetes

** Co will pay 100 million pounds in cash upfront, with up to 50 million pounds tied to sales of Owen Mumford's Aidaptus auto-injector platform over three years - EMBC

** Owen Mumford makes auto-injectors and self-injection devices used to deliver drugs for conditions such as obesity, autoimmune diseases and allergies, co says

** Says the deal will help diversify revenue and support growth using its global sales network

** Transaction is expected to close in fiscal Q3 2026, subject to regulatory approvals; deal funded through borrowings - EMBC

** Shares down ~42% in 2025

($1 = 0.7534 pounds)

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620411212?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 18:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620411212","market":"us","top_or_hot":-1,"title":"BUZZ-Embecta rises after agreeing to buy UK device maker Owen Mumford","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Embecta rises after agreeing to buy UK device maker Owen Mumford</title></head><body><p>** Shares of medical device maker Embecta <span>EMBC.O</span> rise 2% to $8.99 premarket</p><p>** Co says it will buy privately held Owen Mumford in a deal worth up to 150 <span>million pounds ($199.10 million)</span>, expanding into drug‑delivery devices beyond diabetes</p><p>** Co will pay 100 <span>million pounds </span>in cash upfront, with up to 50 <span>million pounds</span> tied to sales of Owen Mumford's Aidaptus auto-injector platform over three years - EMBC</p><p>** Owen Mumford makes auto-injectors and self-injection devices used to deliver drugs for conditions such as obesity, autoimmune diseases and allergies, co says</p><p>** Says the deal will help diversify revenue and support growth using its global sales network</p><p>** Transaction is expected to close in fiscal Q3 2026, subject to regulatory approvals; deal funded through borrowings - EMBC</p><p>** Shares down ~42% in 2025</p><p>($1 = 0.7534 pounds)</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Embecta rises after agreeing to buy UK device maker Owen Mumford</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Embecta rises after agreeing to buy UK device maker Owen Mumford\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-19 18:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Embecta rises after agreeing to buy UK device maker Owen Mumford</title></head><body><p>** Shares of medical device maker Embecta <span>EMBC.O</span> rise 2% to $8.99 premarket</p><p>** Co says it will buy privately held Owen Mumford in a deal worth up to 150 <span>million pounds ($199.10 million)</span>, expanding into drug‑delivery devices beyond diabetes</p><p>** Co will pay 100 <span>million pounds </span>in cash upfront, with up to 50 <span>million pounds</span> tied to sales of Owen Mumford's Aidaptus auto-injector platform over three years - EMBC</p><p>** Owen Mumford makes auto-injectors and self-injection devices used to deliver drugs for conditions such as obesity, autoimmune diseases and allergies, co says</p><p>** Says the deal will help diversify revenue and support growth using its global sales network</p><p>** Transaction is expected to close in fiscal Q3 2026, subject to regulatory approvals; deal funded through borrowings - EMBC</p><p>** Shares down ~42% in 2025</p><p>($1 = 0.7534 pounds)</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EMBC","symbol_name":"Embecta Corp.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nL4N40712K:1","article_id":"2620411212","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620411212","pubTimestamp":1773917415,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Embecta rises after agreeing to buy UK device maker Owen Mumford** Shares of medical device maker Embecta EMBC.O rise 2% to $8.99 premarket** Co says it will buy privately held Owen Mumford in a deal worth up to 150 million pounds , expanding into drugdelivery devices beyond diabetes** Co will pay 100 million pounds in cash upfront, with up to 50 million pounds tied to sales of Owen Mumford's Aidaptus auto-injector platform over three years - EMBC** Owen Mumford makes auto-injectors and self-injection devices used to deliver drugs for conditions such as obesity, autoimmune diseases and allergies, co says** Says the deal will help diversify revenue and support growth using its global sales network** Transaction is expected to close in fiscal Q3 2026, subject to regulatory approvals; deal funded through borrowings - EMBC** Shares down ~42% in 2025  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EMBC":"Embecta Corp.","BK4198":"医疗保健用品"},"translate_title":"BUZZ-Embecta同意收购英国设备制造商Owen Mumford后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EMBC":0.9},"content_text":"BUZZ-Embecta rises after agreeing to buy UK device maker Owen Mumford** Shares of medical device maker Embecta EMBC.O rise 2% to $8.99 premarket** Co says it will buy privately held Owen Mumford in a deal worth up to 150 million pounds ($199.10 million), expanding into drug‑delivery devices beyond diabetes** Co will pay 100 million pounds in cash upfront, with up to 50 million pounds tied to sales of Owen Mumford's Aidaptus auto-injector platform over three years - EMBC** Owen Mumford makes auto-injectors and self-injection devices used to deliver drugs for conditions such as obesity, autoimmune diseases and allergies, co says** Says the deal will help diversify revenue and support growth using its global sales network** Transaction is expected to close in fiscal Q3 2026, subject to regulatory approvals; deal funded through borrowings - EMBC** Shares down ~42% in 2025($1 = 0.7534 pounds) (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620411212","isCrawlerRequest":true}